AGTC Presents Data Demonstrating Efficiency of its AAV Vectors for Ocular Gene Therapy Even in the Presence of Anti-AAV Antibodies

Results show that the presence of neutralizing antibodies (NAbs) to AAV in the serum or in the eye did not affect gene delivery, gene expression, or inflammation following ocular administration of AAV vectors.